Quetiapine as monotherapy for social anxiety disorder: A placebo-controlled study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 7, 2007, Pages 1464-1469

  Vaishnavi, Sandeep ^a   Alamy, Syed ^a   Zhang, Wei ^a   Connor, Kathryn M ^a   Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anxiety disorders; Atypical antipsychotics; Social phobia

Indexed keywords

QUETIAPINE;

ADULT; ARTICLE; BLURRED VISION; BRIEF SOCIAL PHOBIA SCALE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; FEMALE; HEADACHE; HUMAN; MALE; MONOTHERAPY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SHEEHAN DISABILITY INVENTORY; SIDE EFFECT; SOCIAL PHOBIA; SOCIAL PHOBIA INVENTORY; SWEATING; SWELLING; THIRST; TINNITUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DATA INTERPRETATION, STATISTICAL; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SOCIAL BEHAVIOR DISORDERS;

EID: 34548137738     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.06.027     Document Type: Article

References (36)

1. Atmaca M., Kuloglu M., Tezcan E., and Geçici Ö. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17 (2002) 115-119
2. Barnes T.R.E. A rating scale for drug-induced akithisia. Br J Psychiatry 154 (1989) 672-676
3. Barnett S., Kramer M.L., Casat C.D., Connor K.M., and Davidson J.R. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16 4 (2002) 365-368
4. Blanco C., Schneier F.R., Schmidt A., Blanco-Jerez C.R., Marshall R.D., Sanchez-Lacay A., et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety 18 (2003) 29-40
5. Calabrese J.R., Keck P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162 (2005) 1351-1360
6. Cohen J. Statistical power analysis for the behavioral sciences (1988), Lawrence Erlbaum Associates, Inc., Hillsdale, N.J
7. Connor K.M., Davidson J.R., and Churchill L.E. Psychometric properties of the Social Phobia Inventory (SPIN), new rating scale. Br J Psychiatry 176 (2000) 379-386
8. Connor K.M., Davidson J.R., and Churchill L.E. Adverse-effect profile of kava. CNS Spectr 6 10 (2001) 853
9. Davidson J.R., Potts N., Richichi E., Krishnan R., Ford S.M., Smith R., et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13 (1993) 423-428
10. Davidson J.R., Miner C.M., DeVeaugh-Geiss J., Tupler L.A., Colket J.T., and Potts N.L.S. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 27 (1997) 161-166
11. Davidson J.R., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S., et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 61 10 (2004) 1005-1013
12. Gelernter C.S., Uhde T.W., Cimbolic P., Arnkoff D.B., Vittone B.J., Tancer M.E., et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 48 (1991) 938-945
13. Gross R., Olfson M., Gameroff M.J., Shea S., Feder A., Lantigua R., et al. Social anxiety disorder in primary care. Psychiatry Prim Care 27 (2005) 161-168
14. Guy W. ECDEU assessment manual for psychopharmacology. rev edn. (1976), National Institute of Mental Health, Rockville, Maryland
15. Heimberg R.G., Liebowitz M.R., Hope D.A., Davies S., Holt C.S., and Goetz D. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 55 (1998) 1133-1141
16. He J., Xu H., Yang Y., Zhang X., and Li X.M. Chronic administration of quetiapine alleviates the anxiety-like behavioral changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav Brain Res 160 1 (2005) 178-187
17. Hidalgo R.B., Barnett S.D., and Davidson J.R. Social anxiety disorder in review: two decades of progress. Int Clin Psychopharmacol 17 (2001) 115-119
18. Kashmper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 20 (2004) 44-47
19. Kessler R.C., Stein M.B., and Berglund P. Social phobia subtypes in the national co-morbidity survey. Am J Psychiatry 155 (1998) 613-619
20. Leon A.C., Shear M.K., Portera L., and Klerman G.L. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27 (1992) 78-82
21. Magee W.J., Eaton W.W., Wittchen H.U., McGonagle K.A., and Kessler R.C. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53 (1996) 159-168
22. Pande A.C., Davidson J.R., Jefferson J.W., Janney C.A., Katzelnick D.J., Weisler R.H., et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19 (1999) 341-348
23. Pande A., Feltner D.E., Jefferson J.W., Davidson J.R.T., Pollack M., and Stein M.B. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter trial. J Clin Psychopharmacol 24 (2004) 141-149
24. Pallanti S., and Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemiol Mental Health 2 35 (2006) 1-6
25. Rodebaugh T.L., Holaway R.M., and Heimberg R.G. The treatment of social anxiety disorder. Clin Psychol Rev 24 (2004) 883-908
26. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janaus J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 suppl 20 (1989) 22-33
27. Schneier F.R., Johnson J., Hornig C.D., Liebowitz M.R., and Weissman M.M. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 49 4 (1992) 282-288
28. Schneier F.R., Liebowitz M.R., Abi-Dargham A., Zea-Ponce Y., Lin S.-H., and Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 157 (2000) 457-459
29. Schutters S.I., van Megan H.J., and Westenberg H.G. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry 66 4 (2005) 540-542
30. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212 (1970) 11-19
31. Stahl S.M. Essential psychopharmacology (2000), Cambridge University Press, Cambridge, U.K
32. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., and Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280 (1998) 208-713
33. Stein M.B., Fyer A.J., Davidson J.R., Pollack M.H., and Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156 (1999) 756-760
34. Tiihonen J., Kuikka J., Bergstrom K., Lepola U., Koponen H., and Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154 (1997) 239-242
35. Tollefson G.D., Sanger T.M., Beasley C.M., and Tran P.V. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43 (1998) 803-810
36. Van Ameringen M.A., Lane R.M., Walker J.R., Bowen R.C., Chokka P.R., and Goldner E.M. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158 (2001) 275-281